1. Curr Oncol Rep. 2016 Mar;18(3):18. doi: 10.1007/s11912-016-0504-2.

New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in 
Metastatic Colorectal Cancer.

Cohen R(1), Svrcek M(2)(3), Dreyer C(1), Cervera P(2)(3), Duval A(4), Pocard 
M(5)(6), Fléjou JF(2)(3), de Gramont A(5)(7), André T(8)(9)(10)(11).

Author information:
(1)Department of Medical Oncology, Hospital Saint-Antoine, Assistance 
publique-Hôpitaux de Paris, 184, rue du Faubourg-Saint-Antoine, 75012, Paris, 
France.
(2)Department of Pathology, Hospital Saint-Antoine, APHP, 184 rue du Faubourg 
Saint-Antoine, Paris, 75012, France.
(3)University Pierre et Marie Curie (UMPC), Paris VI, 4 Place Jussieu, Paris, 
75005, France.
(4)INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche 
Saint-Antoine, Equipe "Instabilité des Microsatellites et Cancers," Equipe 
labellisée par la Ligue Nationale contre le Cancer, 184 rue du Faubourg 
Saint-Antoine, Paris, 75012, France.
(5)GERCOR, Oncology Multidisciplinary Group, 151 rue du Faubourg Saint Antoine, 
Paris, 75011, France.
(6)Departement of Digestive and Oncologic Surgery, Hospital Lariboisière, APHP, 
2 rue Ambroise Paré, Paris, 75010, France.
(7)Department of Medical Oncology, Institut Hospitalier Franco-Britannique, 4 
rue Kléber, 92300, Levallois-Perret, France.
(8)Department of Medical Oncology, Hospital Saint-Antoine, Assistance 
publique-Hôpitaux de Paris, 184, rue du Faubourg-Saint-Antoine, 75012, Paris, 
France. thierry.andre@aphp.fr.
(9)University Pierre et Marie Curie (UMPC), Paris VI, 4 Place Jussieu, Paris, 
75005, France. thierry.andre@aphp.fr.
(10)INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche 
Saint-Antoine, Equipe "Instabilité des Microsatellites et Cancers," Equipe 
labellisée par la Ligue Nationale contre le Cancer, 184 rue du Faubourg 
Saint-Antoine, Paris, 75012, France. thierry.andre@aphp.fr.
(11)GERCOR, Oncology Multidisciplinary Group, 151 rue du Faubourg Saint Antoine, 
Paris, 75011, France. thierry.andre@aphp.fr.

Recently, colorectal cancer (CRC) subtyping consortium identified four consensus 
molecular subtypes (CMS1-4). CMS1 is enriched for deficient mismatch repair 
(dMMR) and BRAF (V600E) tumors. Intriguingly, this subtype has better 
relapse-free survival but worse overall survival after relapse compared with the 
other subtypes. Growing evidence is accumulating on the benefit of specific 
therapeutic strategies such as immune checkpoint inhibition therapy in dMMR 
tumors and mitogen-activated protein kinase (MAPK) pathway targeted therapy in 
tumors harboring BRAF (V600E) mutation. After reviewing dMMR prognostic value, 
immune checkpoints as major targets for dMMR carcinomas will be highlighted. 
Following, BRAF (V600E) prognostic impact will be reviewed and therapeutic 
strategies with the combination of cytotoxic agents and especially the 
combinations of BRAF and MAPK inhibitors will be discussed.

DOI: 10.1007/s11912-016-0504-2
PMID: 26861657 [Indexed for MEDLINE]